KellBenx Inks $2.5M in VC
KellBenx, a biotech company developing technology for non-invasive prenatal diagnosis of genetic and inherited disorders, has closed on $2.5 million in an initial round of venture financing. The company, formed in 2010 and based in New York, did not disclose the names of its investors. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test, the company said.
21 April 2011•2 mins read
